Novo Nordisk A/S (TSX:NOVO)

Market Cap	365.20B
Revenue (ttm)	69.06B
Net Income (ttm)	22.71B
Shares Out	n/a
EPS (ttm)	5.11
PE Ratio	16.08
Forward PE	15.97
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,076
Average Volume	27,428
Open	25.06
Previous Close	24.80
Day's Range	24.83 - 25.22
52-Week Range	18.44 - 25.92
Beta	n/a
RSI	75.47
Earnings Date	Feb 4, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1923
• Employees: 77,349
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: NOVO

Financial Performance

In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.

Financial numbers in DKK